Bristol-myers Squibb

PARIS, October 21, 2011 - Hepatitis B is one of the most common infectious diseases in the world, with 350 million people worldwide being chronically infected [1] - this compares with 33 million people living with HIV infection [2]- yet there remains a lack of reliable resources for hepatitis B patientsand caregivers PATH B - "Patients and Professionals Acting Together for Hepatitis B" ( - is a new programme that provides information and tools to guide patients through their journey with chronic hepatitis B from diagnosis to long-term disease management A pioneering educational resource, designed to improve the lives of people living with chronic hepatitis B, was launched today at an annual conference organised by Bristol-Myers Squibb in Hong Kong where 26 patient advocacy groups from 14 countries and regions gathered to discuss viral hepatitis.

PARIS, June 20, 2011 - European Commission approves NULOJIX (belatacept), in combination with corticosteroids and a mycophenolic acid and an interleukin-2 receptor antagonist at induction, for prophylaxis of graft rejection in adult patients receiving a kidney transplant First new mode of action for prevention of graft rejection in kidney transplantation in a decade Similar rates of graft and patient survival with better preservation of renal function seen at one year and maintained through three years vs.

PARIS, June 10, 2011 - Five-year follow-up results were presented today from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia(CP-CML) adult patients resistant or intolerant to imatinib mesylate.

PARIS, December 8, 2010 - Bristol-Myers Squibb today announced that SPRYCEL(R) (dasatinib) 100mg once daily received Marketing Authorization from the European Commission for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukaemia in Chronic Phase (CML-CP).

PRINCETON, New Jersey and TOKYO, December 6, 2010 - Bristol-Myers Squibb Company ( (NYSE:BMY) and Otsuka Pharmaceutical Co., Ltd.
Older News
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
Copyright© 2011 The Gaea Times